Further, while targeting PD-1 and its ligands has emerged as a successful therapeutic modality for the treatment of melanoma, renal, and lung cancers (55–57), one of the major irAEs of immune checkpoint therapy is development of diarrhea and colitis (58). The gene discussed is PDCD1; the disease is lung cancer.